ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6"

  • Abstract Number: 2549 • 2013 ACR/ARHP Annual Meeting

    Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?

    Aikaterini Thanou1, Melissa E. Munroe2, Stan Kamp3, Joel M. Guthridge4, Judith A. James5 and Joan T. Merrill6, 1Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as…
  • Abstract Number: 915 • 2013 ACR/ARHP Annual Meeting

    IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA

    Zafar Mahmood1, Khalid Muhammad1, Marc Schmalzing2, Petra Roll3, Kathrina Eckert1, Thomas Dörner4 and Hans-Peter Tony5, 1Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, 2Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 3Rheumatology and Clinical immunology, University of Würzburg, Würzburg, Germany, 4CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 5Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany

    Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B…
  • Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection

    Janet van Adelsberg1, Steven P. Weinstein2, Neil Graham3, Tanya Momtahen4, Chunpeng Fan5 and Stefano Fiore6, 1Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 2Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Program Direction, Sanofi, Bridgewater, NJ, 5Biostatistics, Sanofi, Bridgewater, NJ, 6Clinical Science, Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
  • Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting

    IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma

    Rebecca Alade1, Korsa Khan2, Xu Shiwen3, Christopher P. Denton4 and Voon Ong5, 1Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, 2Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, 3Rheumatology, Royal Free Hospital, London, United Kingdom, 4Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 5Department of Rheumatology, UCL Medical School, London, England

    Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…
  • Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis

    Kevin L. Winthrop1, Tanya Momtahen2, Stefano Fiore3, Steven P. Weinstein4, Janet van Adelsberg5, Richard Wu6 and Neil Graham7, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2Program Direction, Sanofi, Bridgewater, NJ, 3Clinical Science, Sanofi, Bridgewater, NJ, 4Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 6BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
  • Abstract Number: 653 • 2013 ACR/ARHP Annual Meeting

    Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis

    Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi and Osamu Ishikawa, Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan

    Background/Purpose: Raynaud phenomenon is freaquently observed in patients of systemic sclerosis (SSc) and characterized by episodic vasospasm and ischemia of extremities in response to cold or…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology